Opportunities in the C5 inhibitors market include developing next-gen biosimilars and biosuperiors to improve administration frequency and expand treatment indications for diseases like aHUS, SCD, MG, ...

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...

Lead antibody MB0109 targets C1q and uniquely inhibits both classical complement cascade and C1q-mediated macrophage/microglial activation — two key drivers of neuroinflammationMB0109 demonstrated ...

InflaRx (NASDAQ:IFRX) highlighted recent clinical updates and strategic priorities for its complement inhibition platform during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences ...

Women benefit from planning before conception ...

The intellectual property will enhance Liberate Bio’s LNP platform for selective programming of monocytes and macrophages.

So welcome to our second IR went in 2026, focusing this time on the Phase III ALLEGORY results for Gazyva in SLE, which just got presented last Friday at SLEuro. Today's call is scheduled for 60 ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the ...

New findings that snakes thrive without the hunger hormone ghrelin suggest future obesity drugs could safely mute hunger at its source, complementing today’s satiety‑boosting therapies.